Agilent Technologies Inc. today announced its Ki-67 IHC MIB-1 pharmDxis now FDA approved as an aid in identifying patients with early breast cancer at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.

For many metastatic cancer patients, a one-time whole-genome analysis of a biopsy may be enough to identify their treatment options, a new study has found.

Today, WHO and HRP have launched a new guideline to help countries make faster progress, more equitably, on the screening and treatment of this devastating disease.

On July 6, 2021, Agilent Technologies (NYSE: A) announced a strategic collaboration with GenomiCare Biotechnology in a move aimed to advance the application of the latest Next Generation Sequencing (NGS) technology into the clinical and scientific arena.